Welcome to our dedicated page for Meihua International Medical Technologies Co., Ltd. SEC filings (Ticker: MHUA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Meihua International Medical Technologies Co., Ltd. (MHUA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Meihua files annual reports on Form 20-F and current reports on Form 6-K under Commission File Number 001-41291, covering its operations as a manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China.
Through its Form 6-K filings, the company reports a range of material events. These include unaudited condensed consolidated financial statements and management’s discussion and analysis for interim periods, such as the six months ended June 30, 2025, which are incorporated by reference into its registration statements. Other 6-K filings describe private placements of ordinary shares to non-U.S. investors under Regulation S, including agreements to sell tens of millions of ordinary shares and subsequent closings, with stated uses of proceeds for working capital and general corporate purposes.
Corporate governance and capital structure changes are also documented in MHUA’s SEC filings. A Form 6-K dated November 18, 2025 details the results of an extraordinary general meeting where shareholders approved a one-for-one-hundred share consolidation, an increase in authorized share capital and the creation of a dual-class share structure with Class A and Class B ordinary shares, along with the adoption of a 2025 equity incentive plan. Another filing from October 2025 furnishes the notice and proxy materials for that extraordinary general meeting. A separate Form 6-K dated August 21, 2025 reports the resignation of the then chief executive officer, chief financial officer and a director, and the appointment of new executives and an independent director, including information on their roles and compensation arrangements.
Auditor changes and listing-related matters also appear in the filings. In a Form 6-K filed on January 7, 2026, Meihua discloses the dismissal of Kreit & Chiu CPA LLP and the appointment of Li CPA LLC as its independent registered public accounting firm for the year ended December 31, 2025, stating that there were no disagreements with the former auditor. Other filings reference the company’s registration statements on Forms F-3 and F-1 and the incorporation by reference of financial statements and XBRL data.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the key points in each document, helping users quickly understand topics such as share structure changes, private placements, management transitions and auditor appointments. Real-time updates from EDGAR ensure that new Forms 20-F and 6-K, as well as exhibits like proxy statements and financial statements, are available as soon as they are filed. Users interested in MHUA can use this page to review the company’s regulatory history, analyze how it describes its financial condition and capital markets transactions, and monitor ongoing corporate and governance developments.
Meihua International Medical Technologies Co., Ltd. director Jia Wenzhang reported an existing option position in a Form 3/A amendment. The filing shows a stock option with an exercise price of $530.0000 per share, linked to 19.0000 shares of common stock and expiring on June 27, 2032. Following this report, the option position covers a total of 19.0000 underlying common shares held directly.
Meihua International Medical Technologies Co., Ltd. reported that Jia Wenzhang, serving as an Independent Director, filed an initial Form 3 statement of beneficial ownership. The filing shows no reported transactions and no derivative positions, reflecting only the person’s status as a reporting insider.
Meihua International Medical Technologies Co., Ltd. filed an initial Form 3 for reporting person Colin Anna, who serves as an Independent Director of the company. This filing is an initial statement of beneficial ownership and does not report any stock purchases, sales, option exercises, or other transactions.
Meihua International Medical Technologies Co., Ltd. filed an initial Form 3 for officer Wang Ailiang, who is listed as Chairwoman. The filing reports no insider transactions, no current share holdings, and no outstanding derivative positions for her at this time.
Meihua International Medical Technologies Co., Ltd. CEO Lee Leyi has filed an initial insider ownership report on Form 3. The data provided shows no reported transactions or derivative positions, and no current holding entries are listed for this reporting person.
Meihua International Medical Technologies Co., Ltd. filed an initial Form 3 for its CFO, Liao Shilong, reporting his beneficial ownership status in the company’s securities. The filing shows no reported transactions, no reported share acquisitions or dispositions, and no listed derivative positions at the time of this statement.
Meihua International Medical Technologies reports that Nasdaq has moved forward with delisting its securities. Nasdaq staff initially determined to delist the shares in December 2025, and trading of the Company’s class A ordinary shares was suspended and moved to the OTC Marketplace under the symbol “MHUAF” on December 9, 2025.
The Company appealed and attended a hearing before a Nasdaq Hearings Panel on January 27, 2026, but on February 24, 2026 the Panel denied the request to reinstate trading and determined to delist the securities. On March 2, 2026, the Company requested further review of the Panel’s delisting decision by the Nasdaq Listing and Hearing Review Council.
Meihua International Medical Technologies Co., Ltd. has filed a Form F-3 to register up to 520,000 Class A Ordinary Shares for resale by identified selling shareholders, from time to time after the effective date, pursuant to two share purchase agreements dated October 8, 2025 and December 5, 2025.
The prospectus states the company will receive no proceeds from these resale transactions, the shares may be sold at fixed, market-related or negotiated prices, and the company will bear registration costs. The filing notes that trading in the Class A Ordinary Shares was suspended pending a Nasdaq Hearings Panel determination after a delisting notice; the last reported sale price was $9.87 per share on February 23, 2026.
Meihua International Medical Technologies has modified earlier lock-up restrictions on investors in its October 8 and December 5, 2025 private placements. On January 29, 2026, the company entered leak-out agreements that waive the prior 12‑month lock-up on these securities.
Instead of a full resale ban, each purchaser now agrees that, during the leak-out period, sales on any trading day will not exceed 15% of the average daily trading volume over the prior ten trading days, while the ordinary shares trade on specified U.S. exchanges. The leak-out terms apply once the securities are registered for resale or become sellable under Rule 144.